ABSTRACT
We describe aleukemic leukemia cutis (ALC) in a 50-year-old woman who presented with numerous skin nodular lesions and lack of peripheral blood and bone marrow involvement until late in the evolution of her disease. We emphasize the value of immunohistochemical studies to distinguish ALC from cutaneous large cell lymphoma.
Subject(s)
Leukemia, Myeloid , Leukemia , Leukemic Infiltration , Skin/pathology , Diagnosis, Differential , Female , Humans , Leukemia/diagnosis , Leukemia/pathology , Leukemia, Myeloid/diagnosis , Leukemia, Myeloid/pathology , Lymphoma, Large B-Cell, Diffuse/diagnosis , Middle Aged , Skin Neoplasms/diagnosisSubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Child , Cytarabine/therapeutic use , Daunorubicin/administration & dosage , Doxorubicin/administration & dosage , Female , Humans , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Prednisone/administration & dosage , Remission Induction , Thioguanine/administration & dosage , Vincristine/administration & dosageSubject(s)
Leukemia, Myeloid, Acute/pathology , Adolescent , Adult , Aged , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor/analysis , Child , Chromosomes, Human, Pair 15/ultrastructure , Chromosomes, Human, Pair 17/ultrastructure , Female , Hemorrhagic Disorders/etiology , Humans , Leukemia, Myeloid, Acute/blood , Leukemia, Myeloid, Acute/drug therapy , Male , Middle Aged , Translocation, GeneticSubject(s)
Cytarabine/administration & dosage , Leukemia/drug therapy , Mitoxantrone/administration & dosage , Acute Disease , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cytarabine/adverse effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Mitoxantrone/adverse effectsSubject(s)
Antineoplastic Agents/therapeutic use , Leukemia/drug therapy , Acute Disease , Adult , Female , Humans , Male , Middle Aged , PrognosisSubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia/drug therapy , Neoplasm Recurrence, Local/drug therapy , Acute Disease , Adolescent , Adult , Aged , Asparaginase/administration & dosage , Asparaginase/adverse effects , Child , Cytarabine/administration & dosage , Cytarabine/adverse effects , Female , Humans , Male , Middle Aged , Remission InductionABSTRACT
Nineteen adolescents and adults with relapsed acute lymphoblastic leukemia (ALL) were treated with teniposide (VM-26) plus cytarabine (ara-C). Eight patients (42%) achieved complete remission. Infection and bleeding secondary to myelosuppression were the most serious complications seen. Responders received periodic reinductions with VM-26 and ara-C, but all relapsed within 16 weeks from remission. Our data demonstrate the effectiveness of combination chemotherapy with VM-26 plus ara-C in adolescent and adult ALL in relapse and suggest testing of this combination in first-line protocols. For remission maintenance, the association of other drug combinations is necessary.